Neurobiological Technologies Stock Net Asset
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Neurobiological Technologies' long-term financial health and intrinsic value.
Neurobiological |
Neurobiological Technologies Company Net Asset Analysis
Neurobiological Technologies' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Neurobiological Technologies Net Asset | 2.58 M |
Most of Neurobiological Technologies' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobiological Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Neurobiological Technologies has a Net Asset of 2.58 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Neurobiological Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobiological Technologies' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobiological Technologies could also be used in its relative valuation, which is a method of valuing Neurobiological Technologies by comparing valuation metrics of similar companies.Neurobiological Technologies is currently under evaluation in net asset category among its peers.
Neurobiological Fundamentals
| Return On Equity | 1.0 | ||||
| Profit Margin | 0.74 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | (26.24 M) | ||||
| Shares Outstanding | 27.02 M | ||||
| Shares Owned By Institutions | 9.41 % | ||||
| Number Of Shares Shorted | 37.6 K | ||||
| Price To Book | 0.07 X | ||||
| Price To Sales | 0.0004 X | ||||
| Revenue | 6.03 M | ||||
| Gross Profit | 26.35 M | ||||
| EBITDA | 19.54 M | ||||
| Net Income | 4.94 M | ||||
| Cash And Equivalents | 26.49 M | ||||
| Cash Per Share | 0.98 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | 4.78 M | ||||
| Short Ratio | 0.09 X | ||||
| Target Price | 6.0 | ||||
| Beta | -408.27 | ||||
| Market Capitalization | 10.86 K | ||||
| Total Asset | 2.58 M | ||||
| Working Capital | (73 K) | ||||
| Current Liabilities | 73 K | ||||
| Z Score | 27.29 | ||||
| Net Asset | 2.58 M |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Neurobiological Stock
If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |